“Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial”, J of Skin, vol. 10, no. 2, p. s744, Mar. 2026, doi: 10.25251/ppt8ep84.